From: Academic pediatric clinical research: factors associated with study implementation duration
a) All studies, multivariable mixed linear model with a random intercept for year of grant ( n = 139) | ||
Variable | Coefficient (95 % CI) | p -value |
Intercept | 22.3 (18.5;26.1) | |
Funding mechanism (ref. = Government) | <0.001 | |
External | -7.7 (-11.9;-3.5) | <0.001 |
Internal | -5.3 (-9.8;-0.8) | 0.02 |
Number of centers ^{a} | -0.1 (-0.2;0.02) | 0.07 |
Type of study (ref = Observational) | 0.003 | |
Interventional involving drug therapy | 6.0 (0.7;11.3) | 0.03 |
Interventional without drug therapy | 3.5 (-0.3;7.3) | 0.06 |
b) Studies involving drug therapy, using multivariable linear regression ( n = 35) | ||
Variable | Coefficient (95 % CI) | p -value |
Intercept | 14.9 (6.9;22.9) | |
Funding mechanism (ref. = Government) | 0.08 | |
External | -6.7 (-13.2;-0.2) | 0.05 |
Internal | -2.9 (-9.8;4.0) | 0.41 |
Study population (ref. = Mixed population) | 0.01 | |
Pediatric population | 7.8 (1.1;14.5) | |
Placebo-controlled study | 6.6 (0.9;12.3) | 0.01 |
Age-appropriate formulation (ref. = Appropriate) | 0.05 | |
Intermediate at least for one drug of the study | -3.6 (-13.0;5.8) | 0.44 |
Inappropriate at least for one drug of the study | 6.9 (-0.2;14.0) | 0.06 |